CD19 and congenital rubella syndrome: Recent clinical studies have reported little to no inflammatory toxicities (CRS, ICANS) in patients with B cell malignancies following treatment with cord blood (CB)-derived anti-CD19 CAR-NK cells, suggesting that CB-CAR-NK cells may not cause bystander myeloid cell activation (BMCA) (11, 18).